

## ORIGINAL RESEARCH ARTICLE

**RUNNING HEAD:** Physical activity and incident CVD in women with novel risk factors

**TITLE:** Association between physical activity and risk of incident cardiovascular disease in women with novel risk factors: evidence from the UK Biobank cohort

**Authors:** Zhaleh Ataei<sup>1,2</sup>, Leah Wright<sup>1,2</sup>, Sergio Ruiz-Carmona<sup>1,3</sup>, Erin J Howden<sup>1,2</sup>

### **Affiliations:**

<sup>1</sup>Baker Heart and Diabetes Institute, Melbourne, Australia

<sup>2</sup>Baker Department of Cardiometabolic Health, The University of Melbourne

<sup>3</sup>Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Australia

### **Corresponding Author**

Dr Erin J Howden

Cardiometabolic Health and Exercise Physiology Laboratory

Baker Heart and Diabetes Institute

75 Commercial Road

Melbourne, 3004, Australia

Email: [erin.howden@baker.edu.au](mailto:erin.howden@baker.edu.au)

1 **ABSTRACT**

2 **Background:** Previous evidence demonstrates an increased risk of incident cardiovascular  
3 disease (CVD) in women with early menopause and/or adverse pregnancy outcomes. It also  
4 suggests an inverse association between physical activity and risk of incident CVD. However,  
5 this association in women with novel risk factors have not been evaluated. Therefore, we  
6 aimed to address this hypothesis.

7 **Methods:** We explored the data of 253,300 women without a history of CVD or life limiting  
8 conditions from the UK Biobank cohort, we further stratified women with a history of early  
9 menopause and/or complicated pregnancy to investigate how the risks affect incident CVD in  
10 women. We defined early menopause as any history of natural or surgical (bilateral  
11 oophorectomy) menopause < 47 years and adverse pregnancy outcomes as a history of  
12 gestational diabetes, hypertensive disorders of pregnancy, stillbirth or  $\geq$  two miscarriages. We  
13 then classified women into three categories of physical activity based on their responses to  
14 the International Physical Activity Questionnaire. Women with a total MET-min/week of  $\geq$   
15 3000,  $\geq$  600 and < 600 were categorised into high, moderate, and low levels of physical  
16 activity, respectively. We also assessed the dose-response interaction between physical  
17 activity and risk of incident CVD (heart failure (HF), arrhythmia, coronary heart disease  
18 (CHD), and stroke) in our population and adjusted all the models for potential CVD risk  
19 factors.

20 **Results:** During a median follow-up of 13 years, we found a significant increased risk of  
21 incident HF, arrhythmia and CHD in women with early menopause/complicated pregnancy,  
22 compared to women without these risk factors. Higher levels of physical activity reduced the  
23 risk of incident HF (HR 0.81, 95% CI 0.67 0.97) and arrhythmia (HR 0.84, 95% CI 0.75  
24 0.94), compared to a low levels. Moreover, a moderate level of physical activity attenuated

25 the risk of incident arrhythmia (HR 0.82, 95% CI 0.74 0.92). However, no significant  
26 associations were found between physical activity risk of incident stroke or CHD.

27 **Conclusion:** Our study indicates that higher levels of PA significantly attenuate the risk of  
28 HF and arrhythmia in women with novel risk factors and should be recommended to women  
29 to reduce their increased risk of CVD.

30

31 **Keywords:** pregnancy, menopause, pregnancy complications, primary prevention, exercise,  
32 cardiovascular disease

33

34

35

36

37

38

## 39 INTRODUCTION

40 Cardiovascular disease (CVD) is the most common cause of mortality among women<sup>1</sup>.  
41 Despite recognition that gender and sex are important drivers of CVD risk, there remains an  
42 unmet need to understand what the female specific drivers of CVD outcomes and potential  
43 impacts of preventative approaches are. Some traditional risk factors, including diabetes,  
44 smoking and obesity, put women at higher risk of developing CVD than men<sup>1-3</sup>. The risk of  
45 developing coronary heart disease (CHD) conferred by obesity and cigarette smoking is  
46 greater in women compared to men by 18% and 25%, respectively<sup>4</sup>. Moreover, women with  
47 diabetes are at 44% higher risk of incident CVD compared to men.<sup>2</sup> In addition, some  
48 unmodifiable or less modifiable stages in women's lives, like early menopause and  
49 complicated pregnancy, make them even more vulnerable to CVD.<sup>5,6</sup> According to previous  
50 studies, complicated pregnancy and early menopause affect up to 25%<sup>7</sup> and ~10%<sup>8</sup> of  
51 women, respectively. However, currently there is poor recognition of these risk factors to  
52 overall CVD risk stratification and limited evidence of effective prevention approaches.

53 Physical activity is the cornerstone of CVD prevention. It reduces the risk of incident  
54 CVD and attenuates the harmful effects of other adverse behaviours, such as inappropriate  
55 sleep time or high sedentary behaviour, on cardiovascular health.<sup>9-11</sup> Despite additional risk  
56 factors in women, they tend to be less active and are more sedentary than men (33.2%  
57 inactivity in women vs 29.9% in men)<sup>2</sup>. Physical activity is critical to preventing CVD in this  
58 large population. However, the effects of physical activity on the risk of incident CVD in  
59 women with novel risk factors, including early menopause and complicated pregnancy, has  
60 yet to be explored. Determining if physical activity is beneficial in this setting will have  
61 important public health implications, since engaging in physical activity is among the most  
62 simple and accessible methods to prevent CVD. Our aims were two-fold: firstly, to determine  
63 how female-specific risk factors influenced rates of CVD in women in the UK Biobank

64 cohort. Secondly, to understand how physical activity modifies the increased risk of CVD in  
65 women with novel risk factors and to explore what the ideal level of physical activity is  
66 required to prevent developing CVD in this population. We hypothesised that physical  
67 activity would be a modifier of CVD outcomes in women with female-specific risk factors.

## 68 **METHODS**

69 **Study design:** The UK Biobank is a large prospective cohort study involving over 500,000  
70 participants enrolled from 2006-2010 (Northwest Multicentre Research Ethics Committee  
71 (11/NW/0382), Resource number 55469)). At baseline, participants were aged 40-69 years  
72 old and assessed in various centres across England, Wales and Scotland and were followed up  
73 for different outcomes through linkages to national datasets.<sup>12</sup> Women with a previous  
74 history of CVD (N=8813), including heart failure (HF), coronary heart disease (CHD),  
75 arrhythmia, ischemic stroke, or any congenital heart disease were excluded from the study  
76 (Figure 1). We also excluded women with conditions that reduced their projected life  
77 expectancy to less than three years (Alzheimer's disease, kidney failure, chronic obstructive  
78 pulmonary disease (COPD), and liver failure, N=3420). Information regarding the exact  
79 conditions and their related ICD-10 codes can be found in the supplementary section. The  
80 remaining 253,300 women were included in our study. Our analysis was divided into two  
81 stages to assess our aims and hypothesis: 1) To assess how novel risk factors impact the risk  
82 of developing CVD in women; and 2) To investigate how engaging in different levels of PA  
83 interacts with incident CVD in women with novel risk factors. For our second stage, we  
84 excluded women without a history of early menopause or complicated pregnancy in addition  
85 to those with missing physical activity data or responses that were considered as outliers  
86 according to guidelines<sup>13</sup>, giving us a final sample size of 40,952 women (Figure 1).

87

## 88 **Physical Activity Assessment**

89 Physical activity was assessed according to the participants' self-reported responses to the  
90 International Physical Activity Questionnaire (IPAQ)<sup>14</sup>. Individuals responded to questions  
91 regarding the amount and type of physical activity they engaged in the last seven days,  
92 including leisure time, domestic and gardening, as well as work and transport-related physical  
93 activity. A "high level" of physical activity was defined as achieving  $\geq 3000$  MET-min/week  
94 with a combination of different intensity activities or achieving  $\geq 1500$  MET-min/week with  
95 vigorous intensity activities. A moderate level of physical activity was defined as engaging in  
96 vigorous-intensity physical activity of  $\geq 20$  min/day for  $\geq$  three days/week or doing a  
97 moderate-intensity activity for  $\geq$  five days/week and/or walking of  $\geq 20$  min/day or achieving  
98  $\geq 600$  MET-min/week by doing a combination of different intensity activities.

99

#### 100 **Novel Risk factors:**

101 We defined novel risk factors as any history of early onset menopause (any natural or surgical  
102 (bilateral oophorectomy) menopause earlier than 47 years) and/or complicated pregnancy  
103 (positive history of one or more of the following: gestational diabetes, hypertensive disorders  
104 of pregnancy, stillbirth, and/or two or more miscarriages).<sup>6,15</sup> Data regarding the number of  
105 miscarriages and stillbirths and the age of menopause were extracted from the self-reported  
106 questionnaires. Gestational diabetes was defined based on self-reported data and/or related  
107 ICD-10 codes. The data regarding hypertensive disorders of pregnancy were determined by  
108 ICD-10 codes.

109

#### 110 **Endpoints:**

111 We defined the primary endpoints of this study as diagnosis of HF, CHD, arrhythmia, or  
112 ischemic stroke. All the events were reported using ICD-10 codes based on the data from  
113 hospitals/clinics (see table S1 supplementary material for complete list). If more than one

114 event occurred to a participant, we only counted the first one. The number of events for each  
115 endpoint followed this rule, and only one event per participant was counted. Time to event for  
116 each participant was taken from the date of birth and censored at the date associated with the  
117 development of each endpoint or date of death or the date of their last follow-up session,  
118 whichever came first.

119

#### 120 **Covariates:**

121 We adjusted the results for CVD risk factors, including age, smoking status, obesity, alcohol  
122 consumption, diabetes mellitus, hypertension, dyslipidaemia, and history of cancer. Data  
123 regarding the smoking status and alcohol intake frequency (how many times per day, week,  
124 or month) were obtained from self-reported questionnaires. Obesity was defined as BMI  $\geq$   
125 30, calculated based on the participants' responses to height and weight at their baseline  
126 visits. Diagnosis of hypertension, diabetes, dyslipidaemia, and cancer were defined by at least  
127 one of the related ICD-10 codes (supplementary section).

128

#### 129 **Statistical analysis:**

130 We used Cox proportional hazard models to estimate the hazard ratios (HRs) and 95%  
131 confidence intervals (CIs) for incident CVD among women with and without novel risk  
132 factors. To determine how different levels of physical activity attenuate the risk of incident  
133 CVD we compared the effects of moderate and high levels of physical activity on the risk of  
134 incident CVD to the low-level physical activity in women with novel risk factors. Cox  
135 proportional hazard models were used to calculate the new hazard ratios and 95% confidence  
136 intervals. We evaluated the relationship between physical activity as a continuous variables  
137 and incident CVD with cubic spline models. We performed all statistical analyses with R  
138 version 4.2.1.

139

140 **Study ethics:** The UK Biobank received ethical approval from the Northwest Multicentre  
141 Research Ethics Committee (11/NW/0382). All participants gave written informed consent.  
142 This study has been conducted using the UK Biobank Resource under application number  
143 55469.

## 144 **RESULTS**

145 **Baseline characteristic.** Our study consisted of 253,300 women without a history of CVD or  
146 life limiting conditions from the UK Biobank cohort. Baseline characteristics of the included  
147 women are presented in table 1. The mean age at study entry was  $57 \pm 8$  and  $56 \pm 8.0$  years in  
148 women with and without novel risk factors, respectively. Overall, women without novel risk  
149 factors tended to be healthier, compared to women experiencing novel risk factors. Women  
150 with novel risk factors were more likely to smoke, and have obesity, diabetes, hypertension,  
151 dyslipidaemia, and increased incidence of past cancer. Of the 55,930 women with novel risk  
152 factors, 23,627 had a history of complicated pregnancy, and 35,838 experienced early  
153 menopause. There was overlap in novel risk factors in 3535 women. The median follow up  
154 was 13 years in which there were 8833 incidence CVD events in women with novel risk  
155 factors' arm and 21804 in women with no novel risk factors (table 2). The incidence of CVD  
156 event rates were higher for each condition of interest among women with novel risk factors  
157 compared to those without these risk factors.

158

### 159 **Interaction between novel risk factors and CVD outcomes**

160 In adjusted models, women with a history of early menopause had a significant increase in  
161 the risk of incident HF (HR 1.16, 95% CI 1.08 1.25), CHD (HR 1.15, 95% CI 1.10 1.20),  
162 arrhythmia (HR 1.09, 95% CI 1.04 1.14) and ischemic stroke (HR 1.18, 95% CI 1.07 1.29),  
163 compared to women without this risk factor. Similarly, women with a history of complicated



164 pregnancy had a significantly higher risk of incident HF (HR 1.11, 95% CI 1.01 1.22), CHD  
165 (HR 1.17, 95% CI 1.11 1.23) and arrhythmia (HR 1.07, 95% CI 1.01 1.13), compared to ones  
166 without complicated pregnancy. However, there was no increased risk of ischemic stroke (HR  
167 1.09, 95% CI 0.97 1.23) in the adjusted models.

168

### 169 **Physical activity and attenuation of heart failure risk in women with novel risk factors**

170 In the unadjusted models, there was a significant association between physical activity levels  
171 and risk of incident HF demonstrating that both moderate (HR 0.69, 95% CI 0.59 0.82) and  
172 high (HR 0.59, 95% CI 0.49 0.70) levels of physical activity reduce the risk of incident HF  
173 significantly, compared to a low level of physical activity-. However, after adjusting for  
174 confounders, only the association between a high level of physical activity and risk of  
175 developing HF remained significant (HR 0.81, 95% CI 0.68 0.97) (Figure 2). Dose-response  
176 models also showed a reduced risk of HF at a MET-min/week of 3000 (HR 1.10, 95% CI  
177 0.94 1.28), compared to the baseline MET-min/week of 0 (HR 1.37, 95% CI 1.07 1.76)  
178 (Figure 6A).

179

### 180 **Physical activity and attenuation of arrhythmia risk in women with novel risk factors**

181 In the unadjusted models, moderate (HR 0.69, 95% CI 0.62 0.77) and high (HR 0.67, 95% CI  
182 0.60 0.75) levels of physical activity reduced the risk of arrhythmia, compared to low levels  
183 of physical activity. After adjusting for confounders, we observed a non-linear association in  
184 which the risk of arrhythmia decreased by 18% and 16% with moderate and high levels of  
185 physical activity, respectively (Figure 3). The dose-response association, demonstrated a  
186 lower risk of arrhythmia at MET-min/week of 3000 (HR 1.06, 95% CI 0.96 1.16) and 600  
187 (HR 1.13, 95% CI 1.06 1.21), compared to 0 (HR 1.35, 95% CI 1.15 1.59) (Figure 6B).

188

189 **Physical activity and attenuation of coronary heart disease and stroke risk in women**  
190 **with novel risk factors**

191 In the unadjusted models, higher levels of physical activity reduced the risk of incident CHD  
192 compared to a low level of physical activity; however, adjusting the models for confounders  
193 attenuated the effects (Figures 4). Similarly, the association between physical activity and  
194 risk of incident stroke was consistent with that observed for CHD and after adjusting for  
195 confounders, there was no statistically significant relationship between risk of incident stroke  
196 and physical activity (Figures 5).

197

198 **Impact of traditional risk factors on CVD outcomes in women with novel risk factors**

199 In our multivariable models, traditional risk factors including hypertension and dyslipidaemia  
200 were significantly associated with increased risk across all cardiovascular outcomes.  
201 Hypertension demonstrated the strongest association with HF (HR 3.99, 95% CI 3.38 4.72),  
202 arrhythmia (HR 2.94, 95% CI 2.67 3.24) and stroke (HR 3.01, 95% CI 2.45 3.69) compared  
203 to other risk factors (Figures 2,3,5). While for CHD, dyslipidaemia (HR 3.90, 95% CI 3.58  
204 4.24) emerged as the most significant determinant (Figure 4). Other factors, including  
205 diabetes, history of cancer, smoking and obesity were also included in the analysis; however,  
206 their associations with cardiovascular outcomes were less pronounced (Figure 2-5).

207

208 **DISCUSSION**

209 The principal new findings in the new study are as follows: women with a history of novel  
210 CVD risk factors experience a higher frequency of CVD outcomes and have a higher burden  
211 of traditional CV risk factors than women without novel risk factors. Further in this cohort of  
212 higher risk women we found that higher levels of physical activity attenuated the risk of  
213 incident HF and arrhythmia, but not CHD or ischemic stroke. These findings have important

214 implications for public health recommendations for physical activity and highlight a high-risk  
215 group who could benefit from more targeted primary prevention strategies to increase  
216 physical activity levels in this population. Indeed, our analysis of the dose effect of physical  
217 activity on outcomes, identified that 3000 met minutes per week, which is consistent with  
218 current physical activity guidelines, reduced the risk of HF and arrhythmia.

219

220 Both early menopause and complicated pregnancy are recognized contributors to an elevated  
221 risk of CVD. Although a multitude of female-specific factors have been labelled differently in  
222 many different studies, a consistent finding has been that female factors influence CVD  
223 outcomes, primarily through hormonal changes and cardiometabolic risk factors.<sup>6,16</sup> The  
224 increased risk of CVD associated with early menopause is largely attributed to the premature  
225 loss of estrogen, a protective factor against CVD<sup>16</sup>. Consistent with these established  
226 mechanisms, our data showed that early menopause increased the risk of incident HF, CHD,  
227 arrhythmia, and stroke by 16%, 15%, 9%, and 18%, respectively. Similarly, pregnancy  
228 complications, including miscarriages  $\geq 2$ , stillbirth, gestational diabetes, and hypertensive  
229 disorders of pregnancy, were associated with an increase in the risk of incident HF (11%),  
230 CHD (17%), and arrhythmia (7%). Women with a history of complicated pregnancy have an  
231 increased risk of developing CVD risk factors and later CVD<sup>17</sup>. The mechanism for this is  
232 likely multifactorial, with the development of CV risk factors mediated by a combination of  
233 lifestyle factors and vascular and metabolic dysfunction.

234

235 Accordingly, understanding the role of traditional risk factors is crucial for evaluating  
236 cardiovascular outcomes in this population. Hypertension is a strong CVD risk factor for  
237 premature mortality in women<sup>18</sup> and women who have a history of hypertensive disorder of  
238 pregnancy have an increased risk of developing hypertension<sup>19</sup>. In turn this relationship

239 mediates the association with both HF and CAD in this patient group. Similarly,  
240 hyperlipidaemia is the driving factor of CHD development, without which the disease would  
241 not manifest.<sup>20</sup> These patterns were evident in our study where hypertension emerged as the  
242 strongest contributor to an increased risk of HF, arrhythmia and ischemic stroke; while  
243 dyslipidaemia was the primary predictor of the risk of incident CHD, compared to other risk  
244 factors (Figure 2-5). These findings underscore the multifaceted nature of CVD and the  
245 importance of awareness of both traditional and novel risk factors to improve cardiovascular  
246 outcomes in this population. Emerging evidence suggest that optimal dosing of guideline  
247 directed medical therapy may differ for women<sup>21</sup> and less women receive guideline directed  
248 therapy<sup>22</sup>. While we were unable to evaluate the usage of cardioprotective therapy in our  
249 study, our finding suggests a multi-dimensional approach is required to attenuate the  
250 increased risk of CVD.

251  
252 This is the first study to our knowledge that has evaluated whether lifestyle factors influence  
253 CVD outcomes in women with novel risk factors. There is strong rationale for the promotion  
254 of physical activity to all women to mitigate CVD risk, but individuals with increased risk  
255 may benefit from more tailored intervention. Interestingly current physical activity guidelines  
256 are largely derived from studies of males<sup>23</sup> and despite the growing understanding of sex and  
257 gender specific differences in responses to exercise<sup>24,25</sup>. there are no specific physical activity  
258 recommendations for healthy women, nor women with a high CVD risk. Therefore, studies  
259 that focus specifically on women and evaluate higher risk groups of women are essential to  
260 determine the relevance and effectiveness of current physical activity guideline and their  
261 effectiveness in preventing CVD. In this cohort we found that higher levels of physical  
262 activity lowered the risk of HF and arrhythmia incidence in women with novel risk factors.  
263 After adjusting for other confounders only the higher level of physical activity was protective

264 for women developing HF. This is consistent with meta-analysis that reported that higher  
265 levels of physical activity are required to prevent HF<sup>26</sup>. Conversely, in our adjusted models  
266 both moderate and higher levels of physical activity lowered the risk of arrhythmia, which is  
267 also consistent with prior findings demonstrating that more physically activity individuals  
268 have a lower risk of arrhythmia<sup>27</sup> .

269

270 Previous studies have established the protective effects of physical activity on various  
271 cardiovascular outcomes. High levels of physical activity have consistently been associated  
272 with a significantly reduced risk of incident HF, with research indicating a 35% lower risk  
273 among individuals with the highest level of physical activity (four times guidelines  
274 recommended level), compared to a low levels.<sup>28</sup> We demonstrated that a high level of  
275 physical activity (achieving  $\geq 3000$  MET-min/week through a combination of different  
276 intensities of physical activity) is protective against developing HF, compared to a low level  
277 of physical activity. On the other hand, our data showed both moderate ( $\geq 600$  MET-  
278 min/week) and high levels of physical activity attenuate the risk of arrhythmia. Observing a  
279 non-linear relationship, our findings demonstrated that a moderate level of physical activity  
280 was the optimal level to prevent developing arrhythmia and no further significant risk  
281 reduction was achieved in women with a high level of physical activity, compared to those  
282 with a moderate level. This finding has also been observed elsewhere<sup>29</sup>. In contrast, a study  
283 from Azarbal et al., focusing on the data of nearly 82,000 postmenopausal women without a  
284 history of AF, observed a significant inverse association between a high level of recreational  
285 physical activity ( $> 9$  MET-h/week) and risk of incident AF<sup>30</sup>. Variations in study population,  
286 domains of physical activity (recreational vs all domains) and different confounding factors  
287 might be the reason of having varied findings among the studies.

288

289 Interestingly, for CHD and stroke, no significant associations were observed after adjusting for  
290 potential confounding factors. While prior studies have observed that moderate<sup>31</sup> and high<sup>32</sup>  
291<sup>33</sup> levels of physical activity attenuate the risk of incident CHD and stroke, our findings with a  
292 follow up of 13 years do not support this. It is possible that the discrepancy in findings with  
293 prior work is due to the shorter follow up in our study and difficulty in identifying patients  
294 with CHD or stroke prior to experiencing an event. For example, an arrhythmia can be  
295 detected through ECG screening, while an exercise or pharmacological stress test would be  
296 required to detect CHD and this is not routinely performed in HD and this is not routinely  
297 performed in *asymptomatic* people. Whereas, Hummel et al. found that higher levels of total  
298 physical activity (MET-h/day > 3.6) in women had a significantly lower risk of experiencing  
299 a myocardial infarction, compared to a low level of physical activity (MET-h/day ≤ 1.6)<sup>32</sup>.  
300 Apart from differences in study population, variations in the measurement of physical activity  
301 further complicate comparison between the studies.

302

303 The cardiovascular benefits of physical activity are largely due to the beneficial effects on  
304 CVD risk factors e.g. hypertension, dyslipidaemia, glycaemic control and optimal body  
305 composition, however, some of the mechanisms of benefits are yet to be determined<sup>34</sup>.  
306 Sustaining higher levels of physical activity over a lifetime is likely to have provide critical  
307 cardioprotection for maintaining cardiovascular health women. Indeed, we have shown in  
308 women who initiate exercise training in early and mid-life, prior to menopause that exercise  
309 training reduces ventricular stiffness and improves cardiorespiratory fitness<sup>25,35</sup> whereas  
310 other evidence suggests that cardiovascular benefits are blunted in women who increase  
311 physical activity levels after menopause<sup>36</sup>. Importantly women with a lifelong history of  
312 increased physical activity, consistent with the levels observed to be protective in this cohort  
313 of women with novel risk factors, had superior cardiac function and cardiorespiratory fitness

314 than similar aged and younger sedentary women<sup>37</sup>. Physical activity can also contribute to  
315 lowering CVD risk, through better metabolic health with improved insulin sensitivity and  
316 glycaemic control<sup>38</sup>, and better body composition<sup>39</sup>. The consequential impacts of which  
317 decreases the risk of increased adiposity which has been shown to directly increase  
318 inflammation and alter autonomic tone, thereby raising the risk of AF<sup>26,30,40</sup> and HF<sup>41</sup>.

319

## 320 **Strengths and limitations**

321 To our knowledge, this is the first and largest study to assess the interaction between physical  
322 activity and risk of incident CVD in women with novel risk factors; however, some  
323 limitations must be acknowledged. The use of self-reported data may be subject to recall bias  
324 and there is a tendency to overestimate physical activity levels. We chose to evaluate total  
325 physical activity levels to reflect the overall weekly behaviour, recognising that for women in  
326 particular physical activity may be performed outside of structured settings. Physical activity  
327 behaviour was only assessed at baseline in our study, and therefore there may have been  
328 important changes to physical activity during follow-up that could have influenced our  
329 findings. Menopause history was also reported by self-report. Furthermore, while we adjusted  
330 our results for several key CVD risk factors, other risk factors, including female specific such  
331 as preterm delivery, intrauterine growth restriction and small for gestational age, or other risk  
332 factors including diet, sleeping habits and sedentary behaviour should be considered in future  
333 research. Further, the UK Biobank cohort may not be reflective of the general population,  
334 however there is greater than 50% participation from women which strengthens the  
335 generalisability for the focus of this study. Finally, in future studies it would be important to  
336 understand how novel risk factors contribute to different subtypes of HF e.g. heart failure  
337 with preserved ejection fraction which is 2-fold more common in women<sup>42</sup> and what effects  
338 physical activity have in these populations.

339

## 340 CONCLUSION

341 Our study highlights the effect of novel risk factors on CVD outcomes in women, while also  
342 presenting the protective effect of physical activity, specifically on incident HF and  
343 arrhythmia. We showed that guideline recommended physical activity levels of 150 minutes  
344 of moderate-vigorous physical activity or > 3000 met-minutes per week can prevent  
345 arrhythmia; however, to achieve the maximum protective benefit of physical activity against  
346 HF, women with novel risk factors need to engage in physical activity at twice the  
347 recommended levels. These findings reinforce the critical role of physical activity in  
348 mitigating cardiovascular risks and underscores the importance of educational campaigns  
349 designed for women with a history of novel risk factors to inform women about the potential  
350 benefits of physical activity and encourage them to be active. Moreover, our findings  
351 highlight the need for more precise guidelines regarding the optimal level of physical activity  
352 to effectively reduce the risk of incident CVD, specifically in this population.

353

## 354 DECLARATIONS

355 **Authors' Disclosures of Potential Conflicts of Interest.** All other authors have no relevant  
356 financial or non-financial interests to disclose.

357 **Data Sharing Statement.** This research was conducted using the UK Biobank Resource  
358 (<http://www.ukbiobank.ac.uk/>) under application 55469. Data from the UK Biobank is  
359 accessible to eligible researchers via applying to [www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk).

360 **Funding Sources.** EJH was supported by an Australian National Heart Foundation Future  
361 Leader Fellowship (ID: 102536).

## 362 Author Contributions.

363 Conception and design: EJH, LW, SRC



- 364 Collection and assembly of data: ZA
- 365 Data analysis and interpretation: ZA, EJH, LW, SRC
- 366 Manuscript writing: ZA (initial draft), All authors (revisions)
- 367 Final approval of manuscript: All authors
- 368 Accountable for all aspects of the work: All authors
- 369

## 370 References

- 371 1. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero  
372 M, Kunadian V, Lam CSP, Maas A, et al. The Lancet women and cardiovascular  
373 disease Commission: reducing the global burden by 2030. *Lancet*. 2021;397:2385-  
374 2438. doi: 10.1016/s0140-6736(21)00684-x
- 375 2. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular Disease in  
376 Women: Clinical Perspectives. *Circ Res*. 2016;118:1273-1293. doi:  
377 10.1161/circresaha.116.307547
- 378 3. Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A, McGuire  
379 DK, Eliasson B, Gudbjörnsdóttir S. Age at Diagnosis of Type 2 Diabetes Mellitus and  
380 Associations With Cardiovascular and Mortality Risks. *Circulation*. 2019;139:2228-  
381 2237. doi: 10.1161/circulationaha.118.037885
- 382 4. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart  
383 disease in women compared with men: a systematic review and meta-analysis of  
384 prospective cohort studies. *Lancet*. 2011;378:1297-1305. doi: 10.1016/s0140-  
385 6736(11)60781-2
- 386 5. Roa-Díaz ZM, Raguindin PF, Bano A, Laine JE, Muka T, Glisic M. Menopause and  
387 cardiometabolic diseases: What we (don't) know and why it matters. *Maturitas*.  
388 2021;152:48-56. doi: 10.1016/j.maturitas.2021.06.013
- 389 6. Täufer Cederlöf E, Lundgren M, Lindahl B, Christersson C. Pregnancy Complications  
390 and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study. *J Am*  
391 *Heart Assoc*. 2022;11:e023079. doi: 10.1161/jaha.121.023079
- 392 7. Khan SS, Petito LC, Huang X, Harrington K, McNeil RB, Bello NA, Bairey Merz  
393 CN, Miller EC, Ravi R, Scifres C, et al. Body Mass Index, Adverse Pregnancy  
394 Outcomes, and Cardiovascular Disease Risk. *Circ Res*. 2023;133:725-735. doi:  
395 10.1161/circresaha.123.322762
- 396 8. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD,  
397 Limacher MC, Manson JE, Stefanick ML, Allison MA, et al. Menopause Transition  
398 and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A  
399 Scientific Statement From the American Heart Association. *Circulation*.  
400 2020;142:e506-e532. doi: 10.1161/CIR.0000000000000912
- 401 9. Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, Owen N, Powell KE,  
402 Bauman A, Lee IM. Does physical activity attenuate, or even eliminate, the  
403 detrimental association of sitting time with mortality? A harmonised meta-analysis of  
404 data from more than 1 million men and women. *Lancet*. 2016;388:1302-1310. doi:  
405 10.1016/s0140-6736(16)30370-1
- 406 10. Ekelund U, Brown WJ, Steene-Johannessen J, Fagerland MW, Owen N, Powell KE,  
407 Bauman AE, Lee IM. Do the associations of sedentary behaviour with cardiovascular  
408 disease mortality and cancer mortality differ by physical activity level? A systematic  
409 review and harmonised meta-analysis of data from 850 060 participants. *Br J Sports*  
410 *Med*. 2019;53:886-894. doi: 10.1136/bjsports-2017-098963
- 411 11. Chen LJ, Hamer M, Lai YJ, Huang BH, Ku PW, Stamatakis E. Can physical activity  
412 eliminate the mortality risk associated with poor sleep? A 15-year follow-up of  
413 341,248 MJ Cohort participants. *J Sport Health Sci*. 2021. doi:  
414 10.1016/j.jshs.2021.03.001
- 415 12. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P,  
416 Green J, Landray M, et al. UK biobank: an open access resource for identifying the  
417 causes of a wide range of complex diseases of middle and old age. *PLoS Med*.  
418 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779

- 419 13. International Physical Activity Questionnaire.  
420 <https://sites.google.com/view/ipaq/score>.
- 421 14. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt  
422 M, Ekelund U, Yngve A, Sallis JF. International physical activity questionnaire: 12-  
423 country reliability and validity. *Medicine & science in sports & exercise*.  
424 2003;35:1381-1395.
- 425 15. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ, Kuh  
426 D, Hardy R, Avis NE, et al. Age at natural menopause and risk of incident  
427 cardiovascular disease: a pooled analysis of individual patient data. *Lancet Public  
428 Health*. 2019;4:e553-e564. doi: 10.1016/s2468-2667(19)30155-0
- 429 16. Yoshida Y, Chen Z, Baudier RL, Krousel-Wood M, Anderson AH, Fonseca VA,  
430 Mauvais-Jarvis F. Early Menopause and Cardiovascular Disease Risk in Women With  
431 or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women.  
432 *Diabetes Care*. 2021;44:2564-2572. doi: 10.2337/dc21-1107
- 433 17. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA,  
434 Gunderson EP, Stuart JJ, Vaidya D, Epidemiology ObotAHACo, et al. Adverse  
435 Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for  
436 Cardiovascular Disease Prevention in Women: A Scientific Statement From the  
437 American Heart Association. *Circulation*. 2021;143:e902-e916. doi:  
438 doi:10.1161/CIR.0000000000000961
- 439 18. Gerds E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, Cornelissen V,  
440 Diévarf F, Ferrini M, Kahan T, et al. Sex differences in arterial hypertension: A  
441 scientific statement from the ESC Council on Hypertension, the European Association  
442 of Preventive Cardiology, Association of Cardiovascular Nursing and Allied  
443 Professions, the ESC Council for Cardiology Practice, and the ESC Working Group  
444 on Cardiovascular Pharmacotherapy. *European Heart Journal*. 2022;43:4777-4788.  
445 doi: 10.1093/eurheartj/ehac470
- 446 19. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM,  
447 Natarajan P. Long-Term Cardiovascular Risk in Women With Hypertension  
448 During Pregnancy. *Journal of the American College of Cardiology*. 2019;74:2743-  
449 2754. doi: doi:10.1016/j.jacc.2019.09.052
- 450 20. Sallam T, Watson KE. Predictors of cardiovascular risk in women. *Womens Health  
451 (Lond)*. 2013;9:491-498. doi: 10.2217/whe.13.44
- 452 21. Agarwal A, Peters SAE, Chandramouli C, Lam CSP, Figtree GA, Arnott C. Guideline-  
453 Directed Medical Therapy in Females with Heart Failure with Reduced Ejection  
454 Fraction. *Curr Heart Fail Rep*. 2021;18:284-289. doi: 10.1007/s11897-021-00524-z
- 455 22. Sumarsono A, Xie L, Keshvani N, Zhang C, Patel L, Alonso WW, Thibodeau JT,  
456 Fonarow GC, Van Spall HGC, Messiah SE, et al. Sex Disparities in Longitudinal Use  
457 and Intensification of Guideline-Directed Medical Therapy Among Patients With  
458 Newly Diagnosed Heart Failure With Reduced Ejection Fraction. *Circulation*.  
459 2024;149:510-520. doi: 10.1161/circulationaha.123.067489
- 460 23. Blair SN, LaMonte MJ, Nichaman MZ. The evolution of physical activity  
461 recommendations: how much is enough?1234. *The American Journal of Clinical  
462 Nutrition*. 2004;79:913S-920S. doi: <https://doi.org/10.1093/ajcn/79.5.913S>
- 463 24. Bassareo PP, Crisafulli A. Gender Differences in Hemodynamic Regulation and  
464 Cardiovascular Adaptations to Dynamic Exercise. *Curr Cardiol Rev*. 2020;16:65-72.  
465 doi: 10.2174/1573403x15666190321141856
- 466 25. Barnes JN, Fu Q. Sex-Specific Ventricular and Vascular Adaptations to Exercise. *Adv  
467 Exp Med Biol*. 2018;1065:329-346. doi: 10.1007/978-3-319-77932-4\_21

- 468 26. Aune D, Schlesinger S, Leitzmann MF, Tonstad S, Norat T, Riboli E, Vatten LJ.  
469 Physical activity and the risk of heart failure: a systematic review and dose-response  
470 meta-analysis of prospective studies. *Eur J Epidemiol.* 2021;36:367-381. doi:  
471 10.1007/s10654-020-00693-6
- 472 27. Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, Verdicchio  
473 CV, Hendriks JML, Lau DH, La Gerche A, et al. Association between physical  
474 activity and risk of incident arrhythmias in 402 406 individuals: evidence from the  
475 UK Biobank cohort. *European Heart Journal.* 2020;41:1479-1486. doi:  
476 10.1093/eurheartj/ehz897
- 477 28. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de  
478 Lemos JA, Berry JD. Dose-Response Relationship Between Physical Activity and  
479 Risk of Heart Failure: A Meta-Analysis. *Circulation.* 2015;132:1786-1794. doi:  
480 10.1161/circulationaha.115.015853
- 481 29. Jin MN, Yang PS, Song C, Yu HT, Kim TH, Uhm JS, Sung JH, Pak HN, Lee MH,  
482 Joung B. Physical Activity and Risk of Atrial Fibrillation: A Nationwide Cohort Study  
483 in General Population. *Sci Rep.* 2019;9:13270. doi: 10.1038/s41598-019-49686-w
- 484 30. Azarbal F, Stefanick ML, Salmoirago-Blotcher E, Manson JE, Albert CM, LaMonte  
485 MJ, Larson JC, Li W, Martin LW, Nassir R, et al. Obesity, physical activity, and their  
486 interaction in incident atrial fibrillation in postmenopausal women. *J Am Heart Assoc.*  
487 2014;3. doi: 10.1161/jaha.114.001127
- 488 31. Armstrong ME, Green J, Reeves GK, Beral V, Cairns BJ. Frequent physical activity  
489 may not reduce vascular disease risk as much as moderate activity: large prospective  
490 study of women in the United Kingdom. *Circulation.* 2015;131:721-729. doi:  
491 10.1161/circulationaha.114.010296
- 492 32. Hummel M, Hantikainen E, Adami HO, Ye W, Belloc R, Bonn SE, Lagerros YT.  
493 Association between total and leisure time physical activity and risk of myocardial  
494 infarction and stroke - a Swedish cohort study. *BMC Public Health.* 2022;22:532. doi:  
495 10.1186/s12889-022-12923-5
- 496 33. Sattelmair JR, Kurth T, Buring JE, Lee IM. Physical activity and risk of stroke in  
497 women. *Stroke.* 2010;41:1243-1250. doi: 10.1161/strokeaha.110.584300
- 498 34. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of  
499 cardiovascular events: potential mediating mechanisms. *Circulation.* 2007;116:2110-  
500 2118. doi: 10.1161/circulationaha.107.729939
- 501 35. Howden EJ, Sarma S, Lawley JS, Opondo M, Cornwell W, Stoller D, Urey MA,  
502 Adams-Huet B, Levine BD. Reversing the Cardiac Effects of Sedentary Aging in  
503 Middle Age-A Randomized Controlled Trial: Implications For Heart Failure  
504 Prevention. *Circulation.* 2018;137:1549-1560. doi:  
505 10.1161/circulationaha.117.030617
- 506 36. Seals DR, Nagy EE, Moreau KL. Aerobic exercise training and vascular function with  
507 ageing in healthy men and women. *J Physiol.* 2019;597:4901-4914. doi:  
508 10.1113/jp277764
- 509 37. Carrick-Ranson G, Howden EJ, Brazile TL, Levine BD, Reading SA. Effects of aging  
510 and endurance exercise training on cardiorespiratory fitness and cardiac structure and  
511 function in healthy midlife and older women. *Journal of Applied Physiology.*  
512 2023;135:1215-1235. doi: 10.1152/jappphysiol.00798.2022
- 513 38. Thyfault JP, Bergouignan A. Exercise and metabolic health: beyond skeletal muscle.  
514 *Diabetologia.* 2020;63:1464-1474. doi: 10.1007/s00125-020-05177-6
- 515 39. Westerterp KR. Exercise, energy balance and body composition. *European Journal of*  
516 *Clinical Nutrition.* 2018;72:1246-1250. doi: 10.1038/s41430-018-0180-4

- 517 40. Ofman P, Khawaja O, Rahilly-Tierney CR, Peralta A, Hoffmeister P, Reynolds MR,  
518 Gaziano JM, Djousse L. Regular physical activity and risk of atrial fibrillation: a  
519 systematic review and meta-analysis. *Circ Arrhythm Electrophysiol*. 2013;6:252-256.  
520 doi: 10.1161/circep.113.000147
- 521 41. Lopez-Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux  
522 CW, Sattar N, Sun MC, Wittert G, Pinto FJ, et al. Obesity and cardiovascular disease:  
523 mechanistic insights and management strategies. A joint position paper by the World  
524 Heart Federation and World Obesity Federation. *European Journal of Preventive  
525 Cardiology*. 2022;29:2218-2237. doi: 10.1093/eurjpc/zwac187
- 526 42. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R,  
527 Killian JM, Roger VL. A Contemporary Appraisal of the Heart Failure Epidemic in  
528 Olmsted County, Minnesota, 2000 to 2010. *JAMA Internal Medicine*. 2015;175:996-  
529 1004. doi: 10.1001/jamainternmed.2015.0924
- 530
- 531

532 **Table 1. Participants Characteristics**

|                                | <b>Novel risk factors</b><br><b>(N=55930)</b> | <b>Without novel risk factors</b><br><b>(N=197370)</b> |
|--------------------------------|---|--|
| <b>General Characteristics</b> |   |  |
| Age at baseline (year)         | 57.3 ± 7.6                                    | 55.8 ± 8.0   |
| Ethnicity, n (%)               |   |  |
| White                          | 52209 (93.3)                                  | 186,747 (94.6)   |
| Asian                          | 1362 (2.4)                                    | 3686 (1.9)   |
| Black                          | 1164 (2.1)                                    | 3033 (1.5)   |
| Others                         | 1195 (2.2)                                    | 3904 (2.0)   |
| <b>Risk factors</b>            |   |  |
| Smoker, n (%)                  | 31,745 (56.7)                                 | 106623 (54.0)  |
| BMI (kg/m <sup>2</sup> )       | 27.4 ± 5.2                                    | 26.8 ± 5.0   |
| Obesity, n (%)                 | 14431 (25.8)                                  | 43345 (21.9)   |
| Glucose (mmol/L)               | 5.1 ± 1.1                                     | 5.0 ± 0.99   |
| HbA1c (mmol/mol)               | 36.3 ± 6.4                                    | 35.5 ± 5.6   |
| Diabetes Mellitus, n (%)       | 4536 (8.1)                                    | 10150 (5.1)  |
| SBP (mmHg)                     | 138 ± 20                                      | 137 ± 20   |
| DBP (mmHg)                     | 81 ± 10                                       | 81 ± 10  |
| Hypertension, n (%)            | 16,846 (30.1)                                 | 45590 (23.0)   |
| Total cholesterol (mmol/L)     | 4.8 ± 0.9                                     | 4.7 ± 0.9  |
| LDL cholesterol (mmol/L)       | 1.8 ± 0.4                                     | 1.7 ± 0.4  |
| HDL cholesterol (mmol/L)       | 1.4 ± 0.3                                     | 1.4 ± 0.3  |
| Total triglyceride (mmol/L)    | 1.3 ± 0.6                                     | 1.2 ± 0.5  |
| Dyslipidaemia, n (%)           | 7635 (13.6)                                   | 19096 (9.6)  |
| Cancer, n (%)                  | 10272 (18.3)                                  | 32691 (16.5)   |
| <b>Physical Activity</b>       |   |  |
| Summed PA (MET-min/wk)         | 2611 ± 2575.0                                 | 2495 ± 2437.3  |
| Low                            | 7986 (14.3)                                   | 28265 (14.3)   |
| IPAQ n (%) Moderate            | 18235 (32.6)                                  | 66707 (33.8)   |
| High                           | 17101 (30.6)                                  | 59198 (30.0)   |
| Missing                        | 12608 (22.5)                                  | 43200 (21.9)   |

533

534 Acronyms: BMI: Body mass index, HbA1c: Haemoglobin A1c, SBP: Systolic blood  
535 pressure, DBP: Diastolic blood pressure, LDL: Low-density lipoprotein, HDL: High-density  
536 lipoprotein, HRT: Hormone replacement therapy, OCP: Oral contraceptive pills, POP:  
537 Progestogen-only pills, PA: Physical activity, IPAQ: International physical activity  
538 questionnaire.  
539  
540

541 **Table 2. Incidence of CVD Events in women with and without novel risk factors**

|                               | <b>Novel risk factors</b> | <b>Without novel risk factors</b> |
|-------------------------------|---------------------------|-----------------------------------|
|                               | <b>(N=55930)</b>          | <b>(N=197370)</b>                 |
| Heart Failure, n (%)          | 1374 (2.4)                | 3318 (1.7)                        |
| Arrhythmia, n (%)             | 2699 (4.8)                | 7104 (3.5)                        |
| Coronary Heart Disease, n (%) | 3963 (6.6)                | 9449 (4.7)                        |
| Ischemic stroke, n (%)        | 797 (1.4)                 | 1933 (0.9)                        |

542

543

544